Literature DB >> 21443890

Beta blocker metoprolol protects against contractile dysfunction in rats after coronary microembolization by regulating expression of myocardial inflammatory cytokines.

Yongguang Lu1, Lang Li, Xianming Zhao, Weiqiang Huang, Weiming Wen.   

Abstract

AIMS: To examine the effects of metoprolol on expression of myocardial inflammatory cytokines and myocardial function in rats following coronary microembolization (CME). MAIN
METHODS: Male rats were randomly assigned to receive either sham-operation (control group), CME plus saline (CME group), or CME plus metoprolol (metoprolol group). CME was induced by injecting 3000 polyethylene microspheres (42 μm) into the left ventricle during a 10-second occlusion of the ascending aorta. Metoprolol (2.5mg/kg) or saline was administered as three intravenous bolus injections after CME. At 3h, 6h, 12h, 24h and 4 weeks after CME, myocardial function was measured with echocardiography; and the mRNA and protein levels of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10) and interleukin 1-β (IL-1β) were determined. KEY
FINDINGS: Induced CME led to markedly higher mRNA and protein levels of TNF-α, IL-1β and IL-10 at 3, 6, 12, and 24h, as well as reduced left ventricular function, compared to the control group. Metoprolol administration reduced TNF-α and IL-1β levels, but increased IL-10 levels at 3, 6, 12, and 24h compared to the CME group. Moreover, metoprolol treatment resulted in significantly improved left ventricular function at 12h, 24h and 4 weeks, but afforded no cardiac protection at 3h and 12h, compared to the CME group. SIGNIFICANCE: Higher levels of TNF-α and IL-1β in rats following CME are associated with the development of myocardial contractile dysfunction. Metoprolol-conferred protection against progressive contractile dysfunction following CME may be mediated by its anti-inflammation potential.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21443890     DOI: 10.1016/j.lfs.2011.03.012

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Mechanism of programmed cell death factor 4/nuclear factor-κB signaling pathway in porcine coronary micro-embolization-induced cardiac dysfunction.

Authors:  Qiang Su; Lang Li; Jiangyou Wang; You Zhou; Yangchun Liu
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

2.  Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary microembolization in rats.

Authors:  Qiang Su; Lang Li; Yang-Chun Liu; You Zhou; Yong-Guang Lu; Wei-Ming Wen
Journal:  Exp Clin Cardiol       Date:  2013

3.  Ligustrazine Attenuates Myocardial Injury Induced by Coronary Microembolization in Rats by Activating the PI3K/Akt Pathway.

Authors:  Qiang Su; Xiangwei Lv; Ziliang Ye
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

4.  Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart.

Authors:  Feng Zhu; Qiushu Wang; Zhi Wang; Xu Zhang; Benkai Zhang; Hegui Wang
Journal:  Oxid Med Cell Longev       Date:  2022-10-04       Impact factor: 7.310

5.  Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study.

Authors:  Sara Bromander; Rolf Anckarsäter; Marianne Kristiansson; Kaj Blennow; Henrik Zetterberg; Henrik Anckarsäter; Caroline E Wass
Journal:  J Neuroinflammation       Date:  2012-10-24       Impact factor: 8.322

6.  Effect of metoprolol on myocardial apoptosis after coronary microembolization in rats.

Authors:  Qiang Su; Lang Li; Yang-Chun Liu; You Zhou; Wei-Ming Wen
Journal:  World J Emerg Med       Date:  2013

7.  Effects of nicorandil on PI3K/Akt signaling pathway and its anti-apoptotic mechanisms in coronary microembolization in rats.

Authors:  Qiang Su; Lang Li; Jinmin Zhao; Yuhan Sun; Huafeng Yang
Journal:  Oncotarget       Date:  2017-08-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.